Image
illustration
Growth & Buyout Regulatory & Product Launch

SERB SPECIALTY PHARMACEUTICALS acquires the rights from Ipsen to commercialize Xermelo® outside the US and Japan

Monday 4 April, 2022
Body

Xermelo® is indicated for the treatment of Carcinoid Syndrome Diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. CSD is a debilitating condition that can be difficult to manage and severely impacts patients' quality of life.

Content